SAFETY, TOLERABILITY AND IMMUNOGENICITY STUDY OF DIFFERENT VACCINE REGIMENS OF TRIVALENT AD26.MOS.HIV OR TETRAVALENT AD26.MOS4.HIV ALONG WITH CLADE C GLYCOPROTEIN (GP)140 IN HEALTHY HUMAN IMMUNODEFICIENCY VIRUS (HIV)-UNINFECTED ADULTS: